Events

Videos

Podcasts

Articles

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


VEGF Versus mTOR in Non-Clear Cell RCC

Sunitinib Versus Pazopanib in Renal Cell Carcinoma

Managing Untreated Metastatic Renal Cell Carcinoma

Role of Radiation Therapy in Renal Cell Carcinoma

Introduction: Surgical Approaches in mRCC

A trial comparing frontline pembrolizumab with ipilimumab for the treatment of advanced melanoma has met its progression-free survival and overall survival endpoints

Frontline Pembrolizumab Bests Ipilimumab in Phase III Melanoma Trial

OncLive interviewed Jason J. Luke, MD, who discussed the clinical implications of immunotherapies in melanoma, with optimal sequencing and combinations emerging as the most pressing questions that researchers are seeking to answer in ongoing clinical trials.

Anti-PD-1 Therapy Poised to Take the Next Step in Melanoma

Elizabeth A. Mittendorf, MD, PhD, differentiates the main types of immunotherapy, highlights some of the most interesting results in breast cancer trials, and discusses why different types of immunotherapy might be appropriate for different types of breast tumors at various stages of development. 

Hope Rises for Immunotherapy in Breast Cancer

Prostate Cancer: Which Guidelines

Changes in NCCN Guideline: Affecting First-Line

Considerations in Treatment Selection

Sipuleucel-T: Evidence-based Use

Changes in NCCN Guideline: Affecting Second-Line

A Review of Bone-Targeted Therapies

Sequencing: Important Question With Many Answers

Abiraterone: Approval and Use

MAINSAIL: Lessons Learned

Looking Forward: Immunotherapy and Genomics

When to Image: Earlier?

In an interview with OncLive, Ahmad A. Tarhini, MD, PhD, discussed the benefits and challenges of ipilimumab and other immunotherapies and how they could change the adjuvant treatment paradigm for melanoma.

Fresh Insight on Ipilimumab's Potential in the Adjuvant Melanoma Setting

Immuno-Oncology

Immuno-Oncology | Specialty